









Markets
/
Stocks
/
nasdaq-gh
/

Guardant Health Inc

63.380USD

+0.540+0.86%

Close 10/06, 16:00（ET）Quotes delayed by 15 min

7.89BMarket Cap

LossP/E TTM



Guardant Health Inc

63.380

+0.540+0.86%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Guardant Health Inc

Currency: USD Updated: 2025-10-06

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking

24 / 207

Overall Ranking

96 / 4706

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 25 analysts

Buy

Current Rating

66.295

Target Price

+5.50%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Guardant Health Inc Highlights

StrengthsRisks

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 64.39% year-on-year.

Undervalued

The company’s latest PE is -18.94, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 124.14M shares, decreasing 11.70% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 2.82M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-06

The company's current financial score is 6.33, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 232.09M, representing a year-over-year increase of 30.95%, while its net profit experienced a year-over-year increase of 2.66%.

Score

Industry at a Glance

Previous score

6.33

Change



Financials

6.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

5.13

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.86

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

Guardant Health Inc's Company Valuation

Currency: USD Updated: 2025-10-06

The company’s current valuation score is 7.26, which is higher than the Healthcare Equipment & Supplies industry's average of 7.17. Its current P/E ratio is -18.94, which is -42.11% below the recent high of -10.97 and -6.37% above the recent low of -20.15.

Score

Industry at a Glance

Previous score

7.26

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-06

The company’s current earnings forecast score is 8.62, which is higher than the Healthcare Equipment & Supplies industry's average of 7.71. The average price target for Guardant Health Inc is 69.00, with a high of 80.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.62

Change

Support & Resistance

No Data

Analyst Rating

Based on 25 analysts

Buy

Current Rating

66.295

Target Price

+5.50%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

116

Total

Median

Average

Company name

Ratings

Analysts

Guardant Health Inc

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-06

The company’s current price momentum score is 9.28, which is higher than the Healthcare Equipment & Supplies industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 67.91 and the support level at 56.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.36

Change

-0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.599

Buy

RSI(14)

62.364

Neutral

STOCH(KDJ)(9,3,3)

83.397

Overbought

ATR(14)

2.686

Low Volatility

CCI(14)

139.589

Buy

Williams %R

18.451

Overbought

TRIX(12,20)

0.209

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

62.562

Buy

MA10

61.240

Buy

MA20

59.261

Buy

MA50

57.216

Buy

MA100

51.815

Buy

MA200

47.025

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-06

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.33. The latest institutional shareholding proportion is 99.55%, representing a quarter-over-quarter decrease of 7.48%. The largest institutional shareholder is The Vanguard, holding a total of 12.14M shares, representing 9.74% of shares outstanding, with 0.41% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

12.14M

+0.74%

BlackRock Institutional Trust Company, N.A.

8.39M

-2.50%

Capital International Investors

4.98M

-3.33%

Baillie Gifford & Co.

Star Investors

4.81M

-4.96%

Deep Track Capital LP

4.25M

-21.93%

Two Sigma Investments, LP

4.24M

+1.02%

Eventide Asset Management, LLC

3.46M

-3.02%

Invesco Advisers, Inc.

3.40M

+30.20%

Cadian Capital Management LP

3.18M

-30.81%

Citadel Advisors LLC

2.94M

-18.30%

Risk Assessment

Currency: USD Updated: 2025-10-06

The company’s current risk assessment score is 6.06, which is higher than the Healthcare Equipment & Supplies industry's average of 4.58. The company's beta value is 1.54. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.